HNGE
Neutral signalScored 2026-10-24 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Hinge Health, Inc.
- Nom
- Hinge Health, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Information Services
- Bourse
- NYSE
- Capitalisation
- $9.0B
- Employés
- 1,437
- PDG
- Daniel A. Perez
- Site web
- https://www.hingehealth.com
- Marché
- ENOVOMDASNNUSPH
Established in 2012 and headquartered in San Francisco, California, Hinge Health, Inc. creates specialized healthcare software solutions for musculoskeletal and joint health. Their advanced platform is designed to comprehensively manage a spectrum of needs, including general musculoskeletal care, acute injuries, persistent chronic pain, and post-operative rehabilitation. Furthermore, the company provides essential administrative and operational assistance.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 704 100 titres (~64 642 035,98 $ US)
- Insiders
- Mecklenburg Gabriel M.I.Perez Daniel Antonio
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$10,047,017
Avg sell (VWAP, 90d window) $98.77 vs last close $111.71 (+13.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$9,941,141 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-12
- Liquidity
- Liquid $212,502,626/day · 20d vol
- Last synced
-
2026-10-26 21:10:32
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-12 | Budge James | Sell · S · 10b5-1 | 9,420 | $104.33 | $982,836 | Form 4 |
| 2026-10-12 | Mecklenburg Gabriel M.I. | Sell · S · 10b5-1 | 39,868 | $104.34 | $4,159,743 | Form 4 |
| 2026-10-06 | Perez Daniel Antonio | Sell · S · 10b5-1 | 4,100 | $100.20 | $410,811 | Form 4 |
| 2026-09-21 | Pursley James | Sell · S · 10b5-1 | 800 | $95.10 | $76,077 | Form 4 |
| 2026-09-14 | Mecklenburg Gabriel M.I. | Sell · S · 10b5-1 | 29,298 | $94.70 | $2,774,617 | Form 4 |
| 2026-09-11 | Mecklenburg Gabriel M.I. | Sell · S · 10b5-1 | 11,724 | $90.46 | $1,060,511 | Form 4 |
| 2026-09-10 | Budge James | Sell · S · 10b5-1 | 800 | $91.62 | $73,294 | Form 4 |
| 2026-09-10 | Perez Daniel Antonio | Sell · S · 10b5-1 | 1,100 | $91.60 | $100,759 | Form 4 |
| 2026-08-21 | Pursley James | Sell · S · 10b5-1 | 3,411 | $88.68 | $302,492 | Form 4 |
| 2026-08-20 | Leslie Kristina M | Sell · S | 1,200 | $88.23 | $105,876 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-24 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
HNGE combines deeply deteriorating fundamentals (net margin of -89.9%, negative ROE and ROIC) with a near-absent catalyst signal (score 15), dominated by heavy insider selling totaling ~704k shares with zero buys.
The first sentence of the analysis written for HNGE on 2026-10-24 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Pulls against a bullish reading. Current ratio 1.47 · operating margin -93%
Suggested stop 97.93, nearest stored support minus 0.5 ATR(12.3% under the last close). Research, not advice. Not an order.
Recent news
- 2026-10-08 Hinge Health (NYSE:HNGE) CEO Daniel Antonio Perez Sells 4,100 Shares of Company Stock Hinge Health Inc. (NYSE: HNGE - Get Free Report) CEO Daniel Perez sold 4,100 shares of Hinge Health stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $100.20, for a total value of $410,820.00. Following the completion of the sale, the chief executive officer directly owned 4,100 shares
- 2026-10-05 34,721 Shares of Hinge Health Inc. $HNGE Bought by Argent Capital Management LLC Argent Capital Management LLC purchased a new stake in Hinge Health Inc. (NYSE: HNGE) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 34,721 shares of the company''s stock, valued at approximately $3,376,000. Several other large investors have also
- 2026-10-05 Hinge Health to announce third quarter 2026 financial results on November 2, 2026 Hinge Health, Inc. (NYSE: HNGE) announced today that it will report its financial results for the quarter ended September 30, 2026, after the U.S. financial mar
- 2026-10-05 Hinge Health to announce third quarter 2026 financial results on November 2, 2026 SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) announced today that it will report its financial results for the quarter ended September 30, 2026, after the U.S. financial markets close on Monday, November 2, 2026. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relation.
- 2026-10-05 Hinge Health (NYSE:HNGE) Hits New 12-Month High – Still a Buy? Hinge Health Inc. (NYSE: HNGE - Get Free Report) reached a new 52-week high during trading on Monday. The stock traded as high as $99.73 and last traded at $98.6050, with a volume of 973880 shares traded. The stock had previously closed at $97.67. Wall Street Analyst Weigh In A number of equities research analysts have
- 2026-10-01 Hinge Health (NYSE:HNGE) Reaches New 1-Year High – Should You Buy? Hinge Health Inc. (NYSE: HNGE - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $97.95 and last traded at $94.3050, with a volume of 157292 shares traded. The stock had previously closed at $92.45. Analyst Ratings Changes Several brokerages recently issued reports on HNGE. Barclays
- 2026-09-28 3 Healthcare Stocks Showing Why the Sector Still Has Momentum The healthcare sector has performed fairly well so far in 2026 due to several factors: GLP-1 medications continue to drive new business and interest, while groundbreaking AI applications help enhance and accelerate the drug discovery process. On top of that, potential mergers and acquisitions activity, as big pharmaceutical companies face a major patent cliff, could provide opportunities for new firms to stand out.
- 2026-09-24 Hinge Health (NYSE:HNGE) President James Pursley Sells 33,000 Shares of Stock Hinge Health Inc. (NYSE: HNGE - Get Free Report) President James Pursley sold 33,000 shares of Hinge Health stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $94.14, for a total transaction of $3,106,620.00. Following the completion of the sale, the president owned 666,909 shares of
- 2026-09-22 Critical Comparison: Hinge Health (NYSE:HNGE) & CorVel (NASDAQ:CRVL) CorVel (NASDAQ: CRVL - Get Free Report) and Hinge Health (NYSE: HNGE - Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk. Insider and Institutional Ownership 51.4% of CorVel shares
- 2026-09-21 Reasons to Hold Hinge Health Stock in Your Portfolio for Now HNGE''s strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Gross Profit Margin | 79.8% | 77.0% | 66.3% | |
| Ebit Margin | -92.0% | -6.3% | -44.6% | |
| Ebitda Margin | -91.2% | -4.7% | -42.7% | |
| Operating Profit Margin | -92.9% | -8.2% | -44.6% | |
| Pretax Profit Margin | -89.7% | -2.9% | -37.1% | |
| Continuous Operations Profit Margin | -89.9% | -3.1% | -36.9% | |
| Net Profit Margin | -89.9% | -3.1% | -36.9% | |
| Bottom Line Profit Margin | -72.1% | -3.1% | -36.9% | |
| Current Ratio | 1.473 | 2.340 | 2.877 | |
| Quick Ratio | 1.430 | 2.297 | 2.805 | |
| Solvency Ratio | -1.428 | -0.023 | -0.525 | |
| Cash Ratio | 0.574 | 1.207 | 1.276 | |
| Price To Earnings Ratio | -8.666 | -250.400 | -27.022 | |
| Price To Earnings Growth Ratio | -0.002 | 2.807 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.002 | 2.807 | 0.000 | |
| Price To Earnings Diluted Ratio | -8.950 | -250.400 | -27.022 | |
| Price To Earnings Diluted Growth Ratio | -0.003 | 2.807 | 0.000 | |
| Price To Book Ratio | 9.717 | 7.032 | 6.858 | |
| Price To Sales Ratio | 6.257 | 7.506 | 10.010 | |
| Price To Free Cash Flow Ratio | 21.545 | 64.788 | -42.763 | |
| Price To Operating Cash Flow Ratio | 21.456 | 59.799 | -45.851 | |
| Debt To Assets Ratio | 0.011 | 0.016 | 0.025 | |
| Debt To Equity Ratio | 0.021 | 0.027 | 0.037 | |
| Debt To Capital Ratio | 0.021 | 0.026 | 0.036 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.967 | 1.616 | 1.457 | |
| Working Capital Turnover Ratio | 2.325 | 1.148 | 0.000 | |
| Operating Cash Flow Ratio | 0.473 | 0.197 | -0.347 | |
| Operating Cash Flow Sales Ratio | 0.292 | 0.126 | -0.218 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.996 | 0.923 | 1.072 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 21.326 | 4.426 | -4.062 | |
| Capital Expenditure Coverage Ratio | 242.148 | 12.988 | -13.848 | |
| Dividend Paid And Capex Coverage Ratio | 242.148 | 12.988 | -13.848 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.491 | -142.896 | -21.708 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 79.8% | ▲2.8% | ▲5.5% |
| Ebit Margin | -92.0% | ▼-85.8% | ▼-44.4% |
| Ebitda Margin | -91.2% | ▼-86.4% | ▼-45.0% |
| Operating Profit Margin | -92.9% | ▼-84.8% | ▼-44.4% |
| Pretax Profit Margin | -89.7% | ▼-86.8% | ▼-46.5% |
| Continuous Operations Profit Margin | -89.9% | ▼-86.8% | ▼-46.6% |
| Net Profit Margin | -89.9% | ▼-86.8% | ▼-46.6% |
| Bottom Line Profit Margin | -72.1% | ▼-69.1% | ▼-34.8% |
| Current Ratio | 1.473 | ▼-0.867 | ▼-0.757 |
| Quick Ratio | 1.430 | ▼-0.867 | ▼-0.747 |
| Solvency Ratio | -1.428 | ▼-1.405 | ▼-0.769 |
| Cash Ratio | 0.574 | ▼-0.633 | ▼-0.445 |
| Price To Earnings Ratio | -8.666 | ▲241.734 | ▲86.697 |
| Price To Earnings Growth Ratio | -0.003 | ▼-2.809 | ▼-0.937 |
| Forward Price To Earnings Growth Ratio | -0.003 | ▼-2.809 | ▼-0.937 |
| Price To Earnings Diluted Ratio | -8.950 | ▲241.450 | ▲86.507 |
| Price To Earnings Diluted Growth Ratio | -0.003 | ▼-2.810 | ▼-0.937 |
| Price To Book Ratio | 9.717 | ▲2.685 | ▲1.848 |
| Price To Sales Ratio | 6.257 | ▼-1.248 | ▼-1.667 |
| Price To Free Cash Flow Ratio | 21.545 | ▼-43.243 | ▲7.022 |
| Price To Operating Cash Flow Ratio | 21.456 | ▼-38.343 | ▲9.654 |
| Debt To Assets Ratio | 0.011 | ▼-0.006 | ▼-0.007 |
| Debt To Equity Ratio | 0.021 | ▼-0.005 | ▼-0.007 |
| Debt To Capital Ratio | 0.021 | ▼-0.005 | ▼-0.007 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.968 | ▲0.352 | ▲0.287 |
| Working Capital Turnover Ratio | 2.325 | ▲1.177 | ▲1.167 |
| Operating Cash Flow Ratio | 0.473 | ▲0.277 | ▲0.365 |
| Operating Cash Flow Sales Ratio | 0.292 | ▲0.166 | ▲0.225 |
| Free Cash Flow Operating Cash Flow Ratio | 0.996 | ▲0.073 | ▼-0.001 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 21.326 | ▲16.900 | ▲14.096 |
| Capital Expenditure Coverage Ratio | 242.148 | ▲229.161 | ▲161.719 |
| Dividend Paid And Capex Coverage Ratio | 242.148 | ▲229.161 | ▲161.719 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.491 | ▲136.405 | ▲50.541 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Market cap | $3.68B | $2.93B | $2.93B | |
| Enterprise value | $3.48B | $2.64B | $2.71B | |
| EV / Sales | 5.92x | 6.76x | 9.26x | |
| EV / Op. cash flow | 20.29x | 53.89x | -42.42x | |
| EV / Free cash flow | 20.37x | 58.38x | -39.56x | |
| EV / EBITDA | -6.49x | -142.90x | -21.71x | |
| Net debt / EBITDA | 0.37x | 15.68x | 1.75x | |
| Current ratio | 1.47x | 2.34x | 2.88x | |
| Income quality | -0.33x | -4.11x | 0.59x | |
| Graham net-net | $1 | $3 | $3 | |
| Tax burden | 100.2% | 106.0% | 99.6% | |
| Interest burden | 97.5% | 46.1% | 83.2% | |
| Working capital | $171.5M | $334.1M | $345.7M | |
| Invested capital | $255.5M | $414.5M | $432.0M | |
| Return on assets | -70.9% | -1.8% | -17.4% | |
| Operating ROA | -77.1% | -4.9% | 0.0% | |
| Return on tangible assets | -77.9% | -2.0% | -19.4% | |
| Return on equity | -139.6% | -2.9% | -25.3% | |
| Return on invested capital | -141.3% | -7.5% | -29.4% | |
| Return on capital employed | -142.9% | -7.5% | -29.8% | |
| Earnings yield | -14.4% | -0.4% | -3.7% | |
| Free cash flow yield | 4.6% | 1.5% | -2.3% | |
| Capex / Op. cash flow | 0.4% | 7.7% | -7.2% | |
| Capex / Depreciation | 13.8% | 63.4% | 82.0% | |
| Capex / Sales | 0.1% | 1.0% | 1.6% | |
| SG&A / Sales | 108.8% | 58.3% | 73.3% | |
| R&D / Sales | 62.6% | 25.8% | 37.6% | |
| Stock comp / Sales | 109.4% | 0.2% | 0.6% | |
| Intangibles / Total assets | 8.9% | 9.4% | 10.2% | |
| Days sales outstanding | 41d | 40d | 58d | |
| Days payables outstanding | 0d | 0d | 0d | |
| Operating cycle | 89d | 84d | 107d | |
| Cash conversion cycle | 89d | 84d | 107d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years